Ozempic vs Mounjaro vs Retatrutide: Which Weight Loss Drug Wins in 2026?
Three drugs now dominate the weight loss landscape: Ozempic/Wegovy (semaglutide), Mounjaro/Zepbound (tirzepatide), and the upcoming retatrutide. Each produces dramatic weight loss through different mechanisms. This analysis compares them on the metrics that actually matter — efficacy, side effects, cost, and practical considerations.
Key Takeaways
- Retatrutide produces the most weight loss in trials (24.2% at 48 weeks), followed by tirzepatide (22.5% at 72 weeks), then semaglutide (16.9% at 68 weeks). But retatrutide is not yet FDA-approved.
- Semaglutide (Wegovy) has the most long-term safety data, including the landmark SELECT cardiovascular outcomes trial showing 20% reduction in heart attacks and strokes.
- Tirzepatide (Zepbound) beats semaglutide on both weight loss and blood sugar control in head-to-head trials (SURPASS-2). It is the most effective currently available option.
- All three cause GI side effects (nausea, vomiting, diarrhea) in 30-50% of users, mostly during dose escalation. These typically improve after 4-8 weeks.
- Cost without insurance: all three run $800-1,300/month at list price. Novo Nordisk cut Wegovy list price by 70% in early 2026. Insurance coverage varies significantly.
- Muscle loss occurs with all three drugs — 25-40% of total weight lost is lean mass. Resistance training and high protein intake (1.6g/kg) are critical to minimize this.
This content is for informational purposes only and is not medical or legal advice. Full disclaimer
How They Work: Single vs Dual vs Triple Agonism
These three drugs represent an evolution in receptor targeting:
Semaglutide (Ozempic/Wegovy) — Single agonist: Activates only the GLP-1 receptor. This suppresses appetite by acting on brain regions that control hunger (hypothalamus, brainstem), slows stomach emptying, and improves insulin secretion. GLP-1 is the mechanism behind all three drugs, but semaglutide activates only this one pathway.
Tirzepatide (Mounjaro/Zepbound) — Dual agonist: Activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The GIP component adds additional metabolic benefits — improved fat metabolism, enhanced insulin sensitivity, and potentially additive appetite suppression through a separate brain pathway. This dual action explains why tirzepatide consistently outperforms semaglutide in head-to-head trials.
Retatrutide — Triple agonist: Activates GLP-1, GIP, and glucagon receptors. The added glucagon receptor activation is the key innovation — glucagon increases energy expenditure (thermogenesis), promotes liver fat burning, and may reduce appetite through liver-brain signaling. This triple mechanism is why retatrutide produces the highest weight loss seen in any drug trial to date.
The pattern is clear: More receptor targets = more weight loss. But more targets also mean more potential for side effects and less long-term safety data.
Weight Loss Results: The Numbers Head-to-Head
Semaglutide 2.4mg (STEP trials): - STEP 1: 16.9% weight loss at 68 weeks (n=1,961) - STEP 2 (diabetes): 9.6% weight loss at 68 weeks - STEP 5: 15.2% maintained at 2 years (n=304) - ~33% of patients lost >20% body weight
Tirzepatide 15mg (SURMOUNT trials): - SURMOUNT-1: 22.5% weight loss at 72 weeks (n=2,539) - SURMOUNT-2 (diabetes): 14.7% weight loss at 72 weeks - SURMOUNT-3: 26.6% with intensive lifestyle intervention - ~40% of patients lost >25% body weight - 3-year data (SURMOUNT-5): sustained weight loss with continued treatment
Retatrutide 12mg (Phase 2): - 24.2% weight loss at 48 weeks (n=338) - Results achieved faster than either competitor - Phase 3 data pending (TRIUMPH program)
Direct comparison (SURPASS-2): When tirzepatide and semaglutide were tested head-to-head in type 2 diabetes, tirzepatide 15mg produced 2.46% HbA1c reduction vs 1.86% for semaglutide 1mg, and superior weight loss at all dose levels.
The muscle loss concern: In all three drug programs, approximately 25-40% of total weight lost was lean mass (muscle). This is consistent across studies and highlights the importance of resistance training and adequate protein intake during treatment.
Side Effects and Safety: What the Trials Show
GI side effects (the big three): - Nausea: Semaglutide ~44%, Tirzepatide ~31%, Retatrutide ~30-45% (dose-dependent) - Vomiting: Semaglutide ~24%, Tirzepatide ~12%, Retatrutide ~16% - Diarrhea: Semaglutide ~30%, Tirzepatide ~23%, Retatrutide ~22%
Most GI effects are dose-dependent and improve with time. Slow dose escalation reduces their severity.
Serious but rare: - Pancreatitis: Reported at similar low rates across all three (1-2%) - Gallbladder events: Risk increases with rapid weight loss (all three drugs) - Thyroid C-cell tumors: Black box warning on all GLP-1 drugs based on rodent studies; human relevance uncertain
Cardiovascular safety: - Semaglutide: The only one with completed cardiovascular outcomes data — SELECT trial showed 20% reduction in major adverse cardiovascular events. This is a significant advantage. - Tirzepatide: Cardiovascular outcomes trial (SURPASS-CVOT) is ongoing. No safety signals to date. - Retatrutide: Too early for CV outcomes data.
Key safety advantage of semaglutide: With the SELECT trial results, semaglutide is the only weight loss drug proven to reduce heart attacks, strokes, and cardiovascular death. For patients with cardiovascular risk factors, this makes it the evidence-based first choice regardless of slightly lower weight loss percentages.
Cost and Access: The Practical Reality in 2026
List prices (without insurance): - Wegovy (semaglutide): ~$550/month after Novo Nordisk 70% price cut in early 2026 - Zepbound (tirzepatide): ~$1,060/month (Eli Lilly has patient savings programs) - Retatrutide: Not yet available commercially
With insurance: - Coverage varies dramatically by plan. Many commercial plans now cover Wegovy, fewer cover Zepbound - Medicare coverage for GLP-1 weight loss drugs expanded in late 2025 - Prior authorization is typically required for all
Compounded versions: - Compounded semaglutide was widely available at $200-400/month until FDA restrictions tightened in 2026 - Compounded tirzepatide availability has been similarly restricted - Retatrutide is not available through compounding
Practical considerations: - All require weekly injection (subcutaneous, similar to insulin) - Oral semaglutide (Rybelsus) is available for diabetes but at lower doses than Wegovy - Eli Lilly launched oral orforglipron (non-peptide GLP-1) in 2026 — the first pill-form GLP-1 for weight loss
*This content is for educational purposes only. Weight loss medication decisions should be made with your healthcare provider based on your individual medical history and circumstances.*
Frequently Asked Questions
Which is better: Ozempic, Mounjaro, or retatrutide?
Based on clinical trial data: retatrutide produces the most weight loss (24.2%), but is not yet available — it is still in Phase 3 trials. Among approved drugs, Mounjaro/Zepbound (tirzepatide) produces more weight loss (22.5%) than Ozempic/Wegovy (semaglutide, 16.9%) and better blood sugar control. However, semaglutide has more long-term safety data and proven cardiovascular benefits (SELECT trial). The best choice depends on your specific situation — insurance coverage, medical history, and whether cardiovascular protection is a priority. Discuss options with your prescriber.
How much weight can you lose on these drugs?
Average weight loss in clinical trials: Semaglutide 2.4mg (Wegovy): 16.9% body weight (about 35 lbs for a 210 lb person) at 68 weeks. Tirzepatide 15mg (Zepbound): 22.5% body weight (about 47 lbs for a 210 lb person) at 72 weeks. Retatrutide 12mg: 24.2% body weight (about 51 lbs for a 210 lb person) at 48 weeks. These are averages — individual results vary significantly. About 30-50% of patients in trials exceeded these averages, while some responded minimally.
What are the side effects of GLP-1 weight loss drugs?
All GLP-1 drugs share similar GI side effects: nausea (30-50% of users), vomiting (10-25%), diarrhea (15-30%), and constipation (10-20%). These are most common during dose escalation and typically improve after 4-8 weeks at a stable dose. Less common but reported side effects include pancreatitis (rare but serious), gallbladder issues (particularly at higher weight loss), muscle loss (25-40% of weight lost is lean mass), and gastroparesis (delayed stomach emptying). Retatrutide, with its additional glucagon receptor activity, may also reduce appetite through liver-mediated pathways, potentially causing different GI patterns.
Is retatrutide available yet?
As of mid-2026, retatrutide is NOT yet FDA-approved. It is in Phase 3 clinical trials (the TRIUMPH program by Eli Lilly). Phase 2 results published in the New England Journal of Medicine showed 24.2% weight loss at 48 weeks. FDA approval could potentially come in late 2026 or 2027, depending on trial completion and regulatory review timelines. Until then, retatrutide is only available through clinical trial enrollment. It is not available through compounding pharmacies.
Sources
Related Compounds
About this article: Written by the PeptideMark Research Team. Published 2026-06-28. All factual claims are supported by cited sources where available. Editorial methodology · Medical disclaimer